Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Singer

Showing results (91-100 of 133) with videos related to

Pageof 14
Sort By:
Clinical Neuropharmacology|August 2, 2008
Caffeine and progression of Parkinson diseaseDavid K Simon, Christopher J Swearingen, Robert A Hauser, et al.
Parkinsonism & Related Disorders|March 28, 2015
Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's diseaseTheresa A Zesiewicz, Marian Evatt, Camille P Vaughan, et al.
Neurology. Clinical Practice|December 29, 2023
Blepharoclonus in ParkinsonismJason Margolesky, Matthew Feldman, Sarah Marmol, et al.
Parkinsonism & Related Disorders|February 26, 2019
Revisiting eligibility for deep brain stimulation: Do preoperative mood symptoms predict outcomes in Parkinson's disease patients?Marina Sarno, Wendy Gaztanaga, Nikhil Banerjee, et al.
Journal of Parkinson'S Disease|September 7, 2020
Minority Enrollment in Parkinson's Disease Clinical Trials: Meta-Analysis and Systematic Review of Studies Evaluating Treatment of Neuropsychiatric SymptomsDaniel G Di Luca, Jacob A Sambursky, Jason Margolesky, et al.
Parkinsonism & Related Disorders|June 21, 2024
Factors affecting minority enrollment in Parkinson's disease genetic testingSarah Marmol, Lucila Hernández, Matthew Feldman, et al.
Journal of Parkinson'S Disease|October 8, 2015
Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical TrialsPaul A Nausieda, Ann Hsu, Lawrence Elmer, et al.
Journal of Clinical Psychopharmacology|November 6, 2019
A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive DyskinesiaStephen R Marder, Carlos Singer, Jean-Pierre Lindenmayer, et al.
Frontiers in Neurology|December 7, 2020
Novel Variants in <i>LRRK2</i> and <i>GBA</i> Identified in Latino Parkinson Disease Cohort Enriched for Caribbean OriginKaren Nuytemans, Farid Rajabli, Parker L Bussies, et al.
Neuromodulation : Journal of the International Neuromodulation Society|May 24, 2019
Gender Disparities in Deep Brain Stimulation for Parkinson's DiseaseDanielle S Shpiner, Daniel G Di Luca, Iahn Cajigas, et al.
Pageof 14

Showing results (91-100 of 133) with videos related to

Sort By:
Pageof 14
Clinical Neuropharmacology|August 2, 2008
Caffeine and progression of Parkinson diseaseDavid K Simon, Christopher J Swearingen, Robert A Hauser, et al.
Parkinsonism & Related Disorders|March 28, 2015
Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's diseaseTheresa A Zesiewicz, Marian Evatt, Camille P Vaughan, et al.
Neurology. Clinical Practice|December 29, 2023
Blepharoclonus in ParkinsonismJason Margolesky, Matthew Feldman, Sarah Marmol, et al.
Parkinsonism & Related Disorders|February 26, 2019
Revisiting eligibility for deep brain stimulation: Do preoperative mood symptoms predict outcomes in Parkinson's disease patients?Marina Sarno, Wendy Gaztanaga, Nikhil Banerjee, et al.
Journal of Parkinson'S Disease|September 7, 2020
Minority Enrollment in Parkinson's Disease Clinical Trials: Meta-Analysis and Systematic Review of Studies Evaluating Treatment of Neuropsychiatric SymptomsDaniel G Di Luca, Jacob A Sambursky, Jason Margolesky, et al.
Parkinsonism & Related Disorders|June 21, 2024
Factors affecting minority enrollment in Parkinson's disease genetic testingSarah Marmol, Lucila Hernández, Matthew Feldman, et al.
Journal of Parkinson'S Disease|October 8, 2015
Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical TrialsPaul A Nausieda, Ann Hsu, Lawrence Elmer, et al.
Journal of Clinical Psychopharmacology|November 6, 2019
A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive DyskinesiaStephen R Marder, Carlos Singer, Jean-Pierre Lindenmayer, et al.
Frontiers in Neurology|December 7, 2020
Novel Variants in <i>LRRK2</i> and <i>GBA</i> Identified in Latino Parkinson Disease Cohort Enriched for Caribbean OriginKaren Nuytemans, Farid Rajabli, Parker L Bussies, et al.
Neuromodulation : Journal of the International Neuromodulation Society|May 24, 2019
Gender Disparities in Deep Brain Stimulation for Parkinson's DiseaseDanielle S Shpiner, Daniel G Di Luca, Iahn Cajigas, et al.
Pageof 14